Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 2/20 | 0.50 |
| ▸ | TRPM8 | Q7Z2W7 | 2/20 | 0.50 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
| ▸ | CA4 | P22748 | 2/20 | 0.43 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.33 |
| ▸ | KDR | P35968 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | SLC18A3 | Q16572 | 3/20 | 0.32 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.32 |
| ▸ | GSR | P00390 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3914000 | 1.00 | TRPA1 (0.50) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL280337 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL16202652 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL13312942 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL7752845 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL19818246 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL680648 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL3047337 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL22601293 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 | |
| SCHEMBL10070056 | 0.97 | TRPA1 (0.52) | TRPA1TRPM8CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1710223-B1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7332632-B2 | Method for producing aldehyde compound or ketone compound by using microreactor | Ubē Industries, Ltd. (JP) | 2008-02-19 | — | — | US | disclosed |
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | UBE INDUSTRIES, LTD., A CORPORATION OF JAPAN (JP) | 2007-06-28 | — | — | US | disclosed |
| EP-1710223-A1 | PROCESS FOR PRODUCING ALDEHYDE COMPOUND OR KETONE COMPOUND WITH USE OF MICROREACTOR | Ube Industries, Ltd. (JP) | 2006-10-11 | — | — | EP | disclosed |
| EP-0902786-B1 | SYNTHESIS OF CYCLOALKYLDIARYLPHOSPHINES | ALBEMARLE CORP (US) | 2005-06-22 | — | — | EP | disclosed |
| EP-0902786-A1 | SYNTHESIS OF CYCLOALKYLDIARYLPHOSPHINES | ALBEMARLE CORPORATION (US) | 1999-03-24 | — | — | EP | disclosed |
| US-5710340-A | Synthesis of cycloalkyldiarylphosophines | ALBEMARLE CORPORATION (US) | 1998-01-20 | — | — | US | disclosed |
| WO-1997041131-A1 | SYNTHESIS OF CYCLOALKYLDIARYLPHOSPHINES | ALBEMARLE CORPORATION (US) | 1997-11-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149823-A1 | Method for producing aldehyde compound or ketone compound by using microreactor | ADH1C, ADH1A, ALDH1A1 | TRPA1 836/4885TRPM8 1287/4885CA1 1026/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.